NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ:LNTH),
today announced that certain of its existing stockholders (the “Selling
Stockholders”) intend to increase the amount of shares offered for sale
by 500,000 shares of common stock to 2,500,000 shares of common stock.
The Company, as previously announced, will offer 1,000,000 shares of
common stock for sale. The shares offered for sale by the Company and
the Selling Stockholders will be offered pursuant to an effective shelf
registration statement filed with the Securities and Exchange Commission
(the “SEC”) on Form S-3 and a related registration statement on Form
S-3MEF filed with the SEC pursuant to Rule 462(b) under the Securities
Act of 1933. The Company will not receive any proceeds from the sale of
shares by the Selling Stockholders. Credit Suisse will act as
underwriter for the offering.
A shelf registration statement (including a prospectus) relating to the
offering of common stock was filed with the SEC on August 5, 2016 (and
became effective on August 31, 2016) and a related registration
statement was filed with the SEC on November 15, 2016 pursuant to Rule
462(b) under the Securities Act of 1933 (and became automatically
effective upon filing). Before you invest, you should read the
prospectus included in the registration statements and the documents
incorporated by reference therein as well as the prospectus supplement
related to this offering. You may obtain these documents for free by
visiting EDGAR on the SEC website at www.sec.gov.
When available, copies of the prospectus supplement and accompanying
prospectus related to the offering may also be obtained by contacting
Credit Suisse Securities (USA) LLC., Attn: Prospectus Department, One
Madison Avenue, New York, NY 10010, or by calling (800) 221-1037, or by
The offering of these securities will be made only by means of a
prospectus supplement and the accompanying prospectus.
This release shall not constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sale of these securities in
any state or other jurisdiction in which such an offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such state or other jurisdiction. Any offer to
buy the securities may be withdrawn or revoked, without obligation or
commitment of any kind, at any time prior to notice of its acceptance
given after the effective date of the shelf registration statements.
About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.
Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc.
(“LMI”), a global leader in the development, manufacture and
commercialization of innovative diagnostic imaging agents and products.
LMI provides a broad portfolio of products, which are primarily used for
the diagnosis of cardiovascular diseases. LMI’s key products include the
echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid
Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m
Generator), a technetium-based generator that provides the essential
medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe
133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate
pulmonary function and for imaging the lungs. The Company is
headquartered in North Billerica, Massachusetts with offices in Puerto
Rico and Canada.
This press release includes statements that
express our opinions, expectations, beliefs, plans, objectives,
assumptions or projections regarding future events or future results and
therefore are, or may be deemed to be, “forward-looking statements”
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including statements regarding the offering. These
forward-looking statements can generally be identified by the use of
forward-looking terminology, including the terms “anticipates,”
“intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,”
“should,” “could,” “predicts,” “targets,” “hopes” or, in each case,
their negatives or other variations or comparable terminology. By their
nature, forward-looking statements involve risks and uncertainties
because they relate to events and depend on circumstances that may or
may not occur in the future, including risks and uncertainties relating
to the consummation of the proposed offering by the Company and Selling
Stockholders and the risks identified, or incorporated by reference, in
the prospectus supplement or accompanying prospectus.
Lantheus Holdings, Inc.
Meara Murphy, 978-671-8508